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Background: Decision aids are evidence-based tools designed to inform people of the potential benefit and harm
of treatment options, clarify their preferences and provide a shared decision-making structure for discussion at a
clinic visit. For patients with rheumatoid arthritis (RA) who are considering methotrexate, we have developed a
web-based patient decision aid called the ANSWER (Animated, Self-serve, Web-based Research Tool). This study
aimed to: 1) assess the usability of the ANSWER prototype; 2) identify strengths and limitations of the ANSWER from
the patient’s perspective.
Methods: The ANSWER prototype consisted of: 1) six animated patient stories and narrated information on the
evidence of methotrexate for RA; 2) interactive questionnaires to clarify patients’ treatment preferences. Eligible
participants for the usability test were patients with RA who had been prescribed methotrexate. They were asked to
verbalize their thoughts (i.e., think aloud) while using the ANSWER, and to complete the System Usability Scale
(SUS) to assess overall usability (range = 0-100; higher = more user friendly). Participants were audiotaped and
observed, and field notes were taken. The testing continued until no new modifiable issues were found. We used
descriptive statistics to summarize participant characteristics and the SUS scores. Content analysis was used to
identified usability issues and navigation problems.
Results: 15 patients participated in the usability testing. The majority were aged 50 or over and were university/
college graduates (n = 8, 53.4%). On average they took 56 minutes (SD = 34.8) to complete the tool. The mean SUS
score was 81.2 (SD = 13.5). Content analysis of audiotapes and field notes revealed four categories of modifiable
usability issues: 1) information delivery (i.e., clarity of the information and presentation style); 2) navigation control
(i.e., difficulties in recognizing and using the navigation control buttons); 3) layout (i.e., position of the videos, text,
diagrams and navigation buttons); 4) aesthetic (i.e., the colour, look and feel of the online tool).
Conclusions: Although the SUS score indicated high usability before and after major modification, findings from
the think-aloud sessions illustrated areas that required further refinement. Our results highlight the importance of
formative evaluation in usability testing.
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Rheumatoid arthritis (RA) affects about 1% of the popu-
lation worldwide, with the peak onset between age 35
and 50 [1,2]. There is ample evidence supporting early
and persistent use of disease-modifying anti-rheumatic
drugs (DMARD) to prevent irreversible joint damage
[3-5]. Among the available DMARD, methotrexate is
generally considered the first-line treatment for RA
based on its benefits and potential side effects. However,
a Canadian population-based research reported that only
43% of the population with RA had used a DMARD over
a five-year period [6].
Patients’ decisions on medication use can be affected
by their concerns about side effects [7]. Several qualita-
tive studies in chronic disease, including RA, have re-
vealed patients’ ambivalence toward using medication
[8,9]. On one hand, they described an aversion to drugs
because of the anticipated side effects and, on the other
hand, they felt compelled to take medication due to a
fear of the potentially crippling effects of an uncon-
trolled disease. The circumstance in which people de-
cided to use or not use medications appeared to be
influenced by the nature of the symptoms and the extent
to which symptoms disrupt daily lives.
In recent years, clinical practice has been expanding
from traditional authoritative models, in which physi-
cians make treatment decisions for patients, to include
shared decision-making. This involves an exchange of
information to prepare patients to make treatment deci-
sions and engage in the process of decision-making with
their healthcare providers [10,11]. One way to facilitate
shared decision-making is through the use of patient de-
cision aids [12]. These are evidence-based tools designed
to help individuals to choose between two or more treat-
ment options [13,14]. Decision aids help people to
personalize information about treatment effectiveness,
outcomes and the inherent uncertainties of potential
benefit versus potential harm. An important feature of
decision aids is that they help individuals to clarify their
personal values towards benefits and harms, and to com-
municate this information to health professionals. Pa-
tients who have used decision aids tend to have more
knowledge about the treatment, more realistic expecta-
tions and lower decisional conflict compared to those
who received usual care [15]. Also, decision aid users are
more likely to participate in decision-making and to
reach a treatment decision [15].
To assist patients with RA to make decisions about
using methotrexate, we developed an online decision aid
called ANSWER (Animated, Self-serve, Web-based Re-
search Tool) [16]. The innovative aspect of ANSWER is
its built-in patient stories that illustrate common situa-
tions people experience when making decisions about
their treatment, as well as attributes required foreffective management of their healthcare. The primary
objective of this study was to assess the user friendliness
of the ANSWER prototype. Our secondary objective was
to identify strengths and limitations of the tool from the
user’s perspective. This study focuses on the refinement
of the ANSWER prototype so that it could be deployed
for use by the general public.
Methods
Decision aid development
Development of the ANSWER decision aid was guided
by the International Patient Decision Aid Standards
[17,18]. Our target users were individuals who had been
prescribed methotrexate for RA, but were feeling unsure
about starting it. As methotrexate was usually prescribed
at the early stage of RA, we designed the ANSWER with
the needs of newly diagnosed patients in mind. This de-
cision aid focused on two options: 1) to take methotrex-
ate as prescribed; 2) to refuse methotrexate and talk to
the doctor about other treatment options. The design of
the ANSWER was guided by Jibaja-Weiss’s Edutainment
Decision Aid Model [19]. Educative entertainment, or
edutainment, is a process whereby educational messages
are imbedded within an entertaining medium, such as
broadcasting media, e.g., television [20,21] or performing
arts (e.g., theatre) [22], and games [22-25]. Central to
the Edutainment Decision Aid Model is the focus on
making the computer-human interface user-friendly
[19,26]. We assembled a multidisciplinary team, involv-
ing patients/consumers, digital media experts, clinicians
and health researchers, to develop the online tool. The
role of patients/consumers was particularly important as
they had firsthand experience in making treatment deci-
sions. They informed the design of the ANSWER by
sharing their experiences of using computers while hav-
ing joint pain and fatigue. Further, they reviewed the
content of the patient decision aid to ensure it is under-
standable by people without medical background, al-
though no readability program was applied.
Figure 1 presents the navigation path of the ANSWER.
Users were guided to start by completing the Information
Module, the Value Clarification Module, and then the stan-
dardized health outcome measures. However, the tool also
allowed users to access any component without following a
linear path. The Information Module consisted of the latest
evidence on methotrexate compared to placebo from a
Cochrane systematic review [27] and the current evidence-
based recommendations from the 3E (Evidence, Expertise,
Exchange) Initiative [28]. The latter was a multinational
collaboration involving 751 rheumatologists from 17 coun-
tries to develop recommendations for the use of methotrex-
ate in RA using a Delphi process. The design of ANSWER
was guided by our previous qualitative study on the help-
seeking experience of patients with early RA [29], and input
Figure 1 ANSWER navigation pathway*. *The ANSWER is designed to guide patients to navigate each component in sequence. The dash
arrows indicate that patients may also access any component without following a linear path.
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dressed six topics: 1) About RA; 2) About methotrexate; 3)
Side effects of methotrexate; 4) Pregnancy; 5) Alcohol use;
6) Other medication options and adjunctive treatments
(e.g., exercise, joint protection techniques). Recognizing
that patients had different preferences in receivingFigure 2 Sample storyboard for ‘About Methotrexate – Bob’s Story’.information, the information was provided in text, voice
narration and animated vignettes.
Each of the six vignettes was based on a unique, fic-
tional character (Figure 2: Sample Storyboard). We used
the animated graphic novel approach for the animated
component, which is a relatively simple, inexpensive andACTION:
Bob is seen using a workbench at his 
garage. He has various pieces of wood 
laid out in front of him in numerous 
shapes and sizes. He currently has a
decent size piece in a clamp on the 
workbench and he's using a planer on 
it.
CAMERA:
Static, High angle, from behind. 
(Establishing shot)
TIME: N/A
NOTES:
Garage door is OPEN. Daylight pouring 
in.
ACTION:
Bob is sitting in the doctor’s office.
BOB(continued) ....., this... 
Methotrexate,
CAMERA:
High angle, static, wide (establishing 
shot)
TIME: N/A
NOTES: N/A
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sequences. This involved repeatedly photographing real
actors in key poses based on the story script, processing
the images in Photoshop to create a comic-book-
inspired look, and then sequencing the images to create
a limited key-frame animation for the characters. This
animation method also allows us to make modification
to characters’ appearances, so that they appear to be
‘race neutral’ for a multinational audience in Canada.
We used a slow animated sequence of 3–5 frames/
10 seconds, which allowed us the freedom to emphasize
the more important points in the story. Finally, actor
voice-over was added to complete the animated
vignettes.
In the Value Clarification Module, two methods were
used to assist patients to consider the importance of the
consequences from each option. First, they were asked
to rate on a 5-point scale the importance of: 1) improv-
ing joint pain; 2) preventing joint damage; 3) improving
physical function; 4) avoiding side effects; 5) becoming
pregnant /starting a family; 6) drinking alcohol. This was
followed by the second method, in which they indicated
the relative importance by allocating 100 points across
the same six items. Patients were also asked to list their
questions and concerns about using methotrexate and to
indicate their preferred choice out of the two options, or
to declare that they remained uncertain.
The ANSWER tool ends with two standardized health
status questionnaires: the Health Assessment Question-
naire [30] and the RA Disease Activity Index [31,32].
Scores of these measures and the individual’s response
to the value clarification questions were summarized in
a 1-page printable report at the end of the online pro-
gram. Patients could discuss this report with their physi-
cians before reaching a final decision about using
methotrexate. The ANSWER prototype was reviewed by
the research team, patients/consumers (OK, CK, CM)
and a health education consultant (GE) to ensure that
the content was understandable to people without a
research or clinical background.
Usability testing
Guided by the methods outlined by Rubin and Chisnell
[33], we used an iterative testing protocol, whereby we
1) conducted onsite testing with participants to identify
usability issues in the ANSWER prototype, 2) stopped
testing and made modifications when no new issues
were identified, and 3) resumed testing with the modi-
fied version. A usability issue was defined as 1) when a
participant was not able to advance to the next step due
to the decision aid design or a programming error, or 2)
when a participant was distracted by a particular design
or content of the online tool. Prior to the testing, we
recognized that some usability issues would not bemodifiable. For example, because the animated stories
were in their final format, we were unable to change the
animation style or the storylines. We continued the test-
ing until no modifiable usability issues were identified.
Participants were recruited through study flyers posted
at 1) rheumatologists’ offices and community health cen-
tres in Vancouver, 2) Mary Pack Arthritis Program,
Vancouver General Hospital and 3) classified advertise-
ment websites such as Craigslist and Kijiji. Eligible indi-
viduals were patients who had a diagnosis of RA and
had been prescribed methotrexate. After providing writ-
ten informed consent, participants attended a two-hour
testing session at the Arthritis Research Centre of
Canada. The test was conducted in a small meeting
room in the presence of a trained research staff member.
Participants were instructed to use the ANSWER as if
they were looking for information about methotrexate
for RA. We used the concurrent think-aloud approach.
The think-aloud protocol was developed in its current
form by Ericsson and Simon [34], and was introduced to
the field of human-computer interaction by Lewis [35].
Participants were encouraged to verbalize thoughts and
feelings when navigating the decision aid. The research
staff prompted the participant to elaborate on his/her
comments when appropriate or when they fell silent for
a while. For example, participants were asked, “What are
you thinking?” or “Can you describe what are looking
at”, if they fell silent. In addition, the research staff inter-
vened when participants indicated they did not know
how to progress to the next stage while using the AN-
SWER. All sessions were audio-recorded. To capture sit-
uations which might be missed by the audio recording,
the research staff took detailed field notes throughout
the session.
Participants were then asked to complete a question-
naire including the System Usability Scale (SUS) [36]
and socio-demographic and internet use characteristics.
Developed by Brooke [36], the SUS consists of 10 state-
ments that are scored on a 5-point scale of strength of
agreement. The total ranges from 0 to 100, with a higher
score indicating more user-friendly. Originally developed
to measured system usability, the SUS has been adapted
for testing a wide range of technologies, including hard-
ware platforms and software programs [37].
Data analysis
We used descriptive statistics to summarize participant
characteristics and the SUS score after each testing cycle.
No statistical comparisons were conducted between cy-
cles, as hypothesis testing was not a goal of this study.
Audio-recordings were transcribed verbatim. Content
analysis was conducted to identify 1) modifiable usability
issues and navigation problems, and 2) strength and
limitation of the ANSWER design. Our data analysis was
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perience with the ANSWER rather than to prove a pre-
conceived theory. We used a constant comparisons
approach, whereby participants’ experiences in using the
ANSWER were coded. Codes that reveal similar naviga-
tion problems were grouped into categories [38]. The
data were constantly revisited after the initial coding,
until it was clear no new categories emerged. The coding
process was performed by one researcher (LCL) who
read each transcript and attributed a code to sentences
or paragraphs (open coding). Other team members were
also included in the coding process to assess causes of
usability problems from participants’ comments. Axial
coding was performed to develop connections among
the categories of usability problems. LCL was also re-
sponsible for discussing the modifications required with
the software programmer, and supervised the revisions.
We stopped a testing cycle to make modifications when
no new problem was identified. The study protocol was
approved by the University of British Columbia Behav-
ioural Research Ethics Board (Application number: H09-
00898).Results
We recruited 15 eligible participants between August
and October 2010. Of those, 10 participated in Cycle 1
and five tested the revised version in Cycle 2 (Table 1).
We did not identify any new issues in Cycle 2. Over half
of the participants were aged 50 or older, with 85.7%
being women and 53.3% being university or college
graduates. The median disease duration was 5 years
(interquartile range [IQR]: 0.83; 10.00), with participants
in Cycle 1 having a longer median disease durationTable 1 Participant characteristics and experience with intern
All (n = 15) Cycle
Age
20–34 2 (13.3%) 1 (10
35–49 5 (33.3%) 4 (40
50–64 7 (46.7%) 4 (40
65 or older 1 (6.7%) 1 (10
Women 13 (85.7%) 9 (90
University/college graduates 8 (53.3%) 6 (60
Disease duration in Years – Median (IQR) 5.00 (0.83; 10.00) 5.50
Hours spent on Internet per day - Median (IQR) 2.00 (1.00; 3.00) 1.75
Use of internet for:
Email 15 (100.0%) 10 (1
Reading news 4 (26.7%) 3 (30
Entertainment 1 (6.7%) 1 (10
Gaming 7 (46.7%) 5 (50
IQR Interquartile range.(5.50 years [IQR: 0.65; 11:00] versus 2 years [IRQ: 0.92;
15.50]). All participants have used methotrexate. They
all used the internet for emails and 46.7% used it to play
internet games. Participants took an average of 56.80 mi-
nutes (SD = 34.80) to complete the ANSWER. Table 2
presents the total SUS score and the results of individual
items in Cycles 1 and 2. The SUS scores were similar
before and after modification of the online tool (Cycle 1:
81.25, SD = 14.92; Cycle 2: 81.00, SD = 11.81).Modifiable usability issues and changes made
Four categories of modifiable usability issues were identified
during Cycle 1 (Table 3, with examples of participants’
comments). These include 1) Information Delivery, 2)
Navigation Control, 3) Layout, and 4) Aesthetic. Figure 3
presents the screenshots of the ANSWER homepage before
and after modification.Information delivery
All participants commented on the length of the ANSWER
tool. The original version included details of benefits and
risks of methotrexate with each video lasting 6–8 minutes
long. During the testing, participants commented on the
repetitiveness of the information and the video length. In
light of these comments, we added short key messages
throughout the online tool, reduced the video length, and
included subtitles in the videos to highlight important
points. It should be noted that the videos were shortened
by condensing the storyline, not the evidence. The rheuma-
tologist investigators in this team (Lacaille, Tugwell) had
ensured that the change did not compromise the presenta-
tion of evidence.et
1: Before modification (n = 10) Cycle 2: After modification (n = 5)
.0%) 1 (20.0%)
.0%) 1 (20.0%)
.0%) 3 (60.0%)
.0%) 0
.0%) 4 (80.0%)
.0%) 2 (40.0%)
(0.65; 11.00) 2.00 (0.92; 15.50)
(1.00; 2.25) 2.50 (0.88; 3.75)
00.0%) 5 (100.0%)
.0%) 1 (20.0%)
.0%) 0
.0%) 2 (40.0%)
Table 2 ANSWER usability testing results
All (n = 15) Cycle 1: Before
modification (n = 10)
Cycle 2: After
modification (n = 5)
Time to complete ANSWER in minutes (SD) 56.08 (34.80) 55.50 (37.98) 57.00 (33.28)
Modified system usability scale items (SD)
(1 = Strongly disagree; 5 = Strongly agree):
1. I liked using ANSWER as a tool for making an informed decision about using
methotrexate as a treatment option for my RA
4.13 (1.06) 4.20 (1.23) 4.00 (0.71)
2. I found ANSWER unnecessarily complex 1.20 (0.56) 1.10 (0.32) 1.40 (0.89)
3. I thought ANSWER was easy to use 4.07 (1.34) 3.80 (1.55) 4.60 (0.55)
4. I think I would need the support of a technical person to be able to use
ANSWER
1.60 (1.06) 1.70 (1.25) 1.40 (0.55)
5. I found the content and navigation in ANSWER was well integrated 3.73 (1.10) 3.60 (1.27) 4.00 (0.71)
6. I thought there was too much inconsistency between the design and
navigation of ANSWER
1.87 (1.19) 1.60 (0.84) 2.40 (1.67)
7. I would imagine that most patients with RA would learn to use ANSWER very
quickly
4.47 (1.06) 4.50 (1.27) 4.40 (0.55)
8. I found ANSWER very cumbersome to use 1.73 (1.39) 1.50 (1.27) 2.20 (1.64)
9. I would be very confident using ANSWER 4.13 (1.19) 4.00 (1.41) 4.40 (0.55)
10. I would need to learn a lot of things about using computers before I could
get going with ANSWER
1.67 (0.90) 1.70 (1.06) 1.60 (0.55)
Total System Usability Scale score (SD) 81.17 (13.53) 81.25 (14.92) 81.00 (11.81)
(Scores of the 10 items were transformed into a summary score ranging from 0
to 100; higher = more user friendly)
Li et al. BMC Medical Informatics and Decision Making 2013, 13:131 Page 6 of 12
http://www.biomedcentral.com/1472-6947/13/131Navigation control
Participants found it difficult to use the control buttons
to access the narrated content, adjust volume and con-
trol the videos. In the original version, we created our
own navigation buttons for the ANSWER with the intent
to achieve a unique look. This, however, became prob-
lematic during the usability testing. While some partici-
pants did not recognize these buttons, others did not
know how to operate them. One participant commented
that average internet users might be more comfortable
with the YouTube navigation buttons and format (Bob,
Table 3). Based on the feedback, we subsequently re-
placed the navigation controls with the YouTube format.
Further, the button size was enlarged to increase ease of
use for patients with hand pain.
Layout
In the original version, each webpage under the tab ‘Ani-
mated Stories’ started with the videos, followed by written
summaries of the information. Participants found the for-
mat unfriendly to navigate, especially for people who pre-
ferred to watch the video and browse the text at the same
time. One participant commented that this layout required
a lot of scrolling up and down with a mouse, which was
particularly difficult for people with RA as the hand joints
were often affected (Jamie, Table 3). In the revised version,
we further condensed the key messages to reduce scrolling
with a mouse within a webpage. In addition, we addedhyperlinks throughout the tool to improve access to the
videos and written information.
Aesthetic
A major criticism of the original ANSWER tool was its
aesthetic. One participant commented that the colour
was ‘flat and uninteresting’ (Theresa, Table 3). Another
participant felt that it needed more colour to make the
site ‘a little more fun’ and more inviting (Jamie). Based
on the feedback, we included pictures in the introduc-
tory pages and throughout the Value Clarification Mod-
ule. In addition, we added colourful screenshots from
the animated stories in the Information Module.
Limitations and strengths of the ANSWER patient decision
aid
Although some components of the ANSWER were not
modifiable (e.g., storylines of the animated videos), we
acknowledged participants’ comments regarding limita-
tions of this online tool. Four additional themes related
to limitations and strengths of the ANSWER emerged in
our analysis. These included 1) authenticity, 2) informa-
tion accuracy about living with arthritis, 3) modeling
shared decision making, and 4) ease of use (Table 4).
In general, participants from both cycles were able to
relate to the characters in one or more patient stories,
although some preferred the stories told by real actors
or patients rather than animated characters. Also, they
Table 3 Modifiable usability issues identified by participants in testing cycle 1 and changes made
Category Examples of participant comment Changes made
1. Information Delivery: clarity of the
information and presentation style.
• The narration is a bit long…a little bit repetitive.
(Jamie – female, age group: 35–49)
Added key messages for users who prefer a
summary of the narrated content.
• Six video clips. That’s quite a lot especially eight
minutes long. (Theresa – female, age group:
50–64)
• Reduced the length of videos. The final version
ranged from 4 minutes 26 seconds to 7 minutes
55 seconds.
• (On videos) I think it’s a bit long winded. You
could have said the same thing with about
2 minutes less so that’s like saying a bit boring
for someone to watch him doing the same thing
twice or three times. (Sherly – female, age group:
50–64)
• Added subtitles to highlight important points
in the video.
2. Navigation Control: Difficulties in
recognizing and using buttons to start/stop
the narrated content, adjust volume, and
control videos.
• This could be a different colour maybe, the
narration (button), just because I didn’t see it right
away, I went straight to the text to read.
(Bob – male, age group: 35–49)
• Used the YouTube format for all videos.
• Enlarged the size of buttons.
• (On accessing the videos) Well I’d be curious
so what I would do is I would probably click on,
my first inclination is to click this because, you
know, you are programmed by YouTube to do
that. I saw the narration button later and that’s
why I was like, oh, okay, now what do I do?
(Bob – male, age group: 35–49)
• Added labels to navigation controls when
appropriate.
3. Layout: Positions of the video, text,
diagrams and navigation buttons.
• (A comment on watching video and reading
information at the same time) …I lose the video
so I am like back and forth, back and forth. Keeps
me busy, keeps me entertained, but not all (the
time), you know, especially when you are dealing
with people with arthritis before medication, your
hands are not just scrolling down, trust me, it’s
very, very hard. (Jamie – female, age group:
35–49)
• Further condensed the key points in order to
reduce scrolling with a mouse while viewing a
webpage.
• Revised the webpage layout and added
hyperlinks for easy access to key summaries and
video.
4. Aesthetic: The colour and ‘look and feel’ of
the program.
• For aesthetics it might be nice to have a
coloured box around each one of these
(diagrams)…I don’t know if you can make them
all the same or each one different colours
because it (the website) looks kind of bland…Or it
doesn’t look like a great beginning where none
of these really jump out at me… (Bob – male,
age group: 35–49)
• Added pictures in the introductory pages and
throughout the value elicitation module.
Added a screenshot of the animated story at the
top of each page of the information module. A
hyperlink was set up to direct people to see the
video in a bigger YouTube viewer.
• As to the colour and layout, I think it needs, it’s
kind of flat and uninteresting… (Theresa –
female, age group: 50–64)
• Probably add a little more just colour. Make it a
little more fun so you can actually like you are
eager to go into the site. (Jamie – female, age
group: 35–49)
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were well integrated in the context of everyday life of
people with RA. For example, one participant remarked
positively about the realistic depiction of fatigue in the
stories (Jamie, Table 4). Participants also commented
that the patient stories were helpful because the main
characters demonstrated shared decision-making behav-
iours, such as considering pros and cons of treatment
options and communicating questions and concerns
with health professionals. Finally, although participants
felt in general that the ANSWER was user-friendly, somecriticised the videos as less polished compared to other
existing patient education programs that used real pa-
tients or actors (Table 4).
Discussion
In this study, we employed rigorous methodology to as-
sess the usability of a new online decision aid for pa-
tients with rheumatoid arthritis. Our results showed that
the ANSWER prototype was user-friendly even before
modifications were made (overall SUS score before
modification: 81.25, SD = 14.92; after modification:
Before modification
After modification
Figure 3 ANSWER homepage – before and after modification.
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Table 4 Themes illustrating limitations and strengths of the ANSWER design
Category Participant comments
1. Authenticity: Participants were able to relate to the patient stories, as
they cover different age groups and sexes. However, some preferred real
actors as compared to the animated characters.
• …it seems like real information, real people talking about the disease,
pros and cons, you know, the fear to take it, uh, the fears or stopping it
could happen; are they going to be able to work? The fear of losing a job.
So those are real situations. It just makes the site a little more human and
realistic. It’s not just scientific information. (Jamie – female, age group:
35–49; C1)
• (On ‘Rosa: About RA video’) I kind of related to it just because, well…,
because my daughter’s, like I did have problems, like I did start flaring up.
I was in remission and then I flared up after. So I was kind of relating to
her …and then hearing her (Rosa) talk to her father really made me sad
to actually go back to my parents’ place while my husband was working
and stay there for the week. It was tough, but yeah, I can relate to it.
(Amy – female, age group: 20–34; C1)
• I think the information is very plentiful, but I think what people, what the
layman person to look at this website is going to need to know more
personable, real stories from people that are like not acting, not – you
know people that are actually taking the drug on a regular basis what
they’re going through. (Rosemary – female, age group: 35–49; C1)
• It might be good overall if these were real video clips (with actors).
(Sheila – female, age group: 50–64; C2)
2. Information accuracy about living with arthritis: Key feature of RA
was fairly portrayed.
• People surrounding, you know, patients, um, with RA, they don’t know
like…that tiredness you feel at all times the people around you they don’t
really understand. So if someone in my family or within, you know, a
family watches this they might go like, oh it’s true, I mean she’s not like
making it up, um, she is actually tired; it’s part of the information, so that’s
something that haven’t seen in any of the websites to be honest.
(Jamie – female, age group: 35–49; C1)
3. Modeling shared decision-making: Some participants commented
on the ability of ANSWER to provide examples of active and engaged
patients.
• I think we’re moving away from the old style where you just did
whatever your doctor told you and didn’t ask questions. And (ANSWER) is
helpful in expanding people’s thinking about it. As far as I can see it
touched on the key decision point. So it’s good for that. (Theresa –
female, age group: 50–64; C1)
4. Ease of use: Participants commented on the user friendliness, but
they were also hoping for a more sophisticated software product
• It was user-friendly definitely. Yeah, I feel it wasn’t sophisticated enough.
I mean methotrexate is a big name and it was a little gimmicky at some
point (of the video presentation), maybe because of the graphics you know.
(Jane – female, age group: 50–64; C2)
C1 Usability Testing Cycle 1, C2 Usability Testing Cycle 2.
RA Rheumatoid Arthritis.
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appeared to be similar, although the small sample size
hindered the opportunity for hypothesis testing. There is
no consensus on what constitutes an acceptable SUS
score [36], however Bangor et al. [37] reviewed the
measurement properties of the SUS and suggested that
products with SUS scores between the high 70s and 80s
were considered ‘good products’. Programs scoring
below 70 required further improvement and those in the
low 70s were considered ‘passable’. Products scoring 90
and above were deemed ‘superior’. Based on their rec-
ommendation, the ANSWER has met the standard of a
user friendly program. It should be noted that we de-
signed the ANSWER for patients to use at their own
pace. Although participants were asked to complete the
ANSWER in one testing session, we expect that in real-
ity some might complete the online tool in several
sessions.It was expected the usability of a new product could
be improved by addressing issues identified during the
usability testing and that this might translate into an im-
proved SUS. What was interesting in this study was that
although the SUS score was high and met the standard
as a good product in Round 1, the formative evaluation
identified a number of modifiable usability issues. This
supports the use of the formative evaluation along with
the summative evaluation in usability testing. The small
change in the SUS score between Round 1 and Round 2
might be due to the non-modifiable issues, including
those raised about the videos. However, given the small
sample size in each round, a direct comparison would
not be possible.
Our study also demonstrated the value of formative
usability testing. Despite the favourable SUS scores in
Cycle 1, participants identified a number of usability is-
sues. Our findings were similar to the usability issues
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example, Stinson et al. [39] tested an electronic chronic
pain diary for adolescents with arthritis and found the
slider controls of pain visual analogue scales difficult to
operate. These slider controls were subsequently modi-
fied to improve user experience. In another study evalu-
ating an online self-management program for youth with
juvenile idiopathic arthritis, Stinson et al. [40] uncovered
performance errors and design issues that were modifi-
able to improve user satisfaction. Recently, in a full scale
usability evaluation of an online interactive game for
patients making treatment decisions for prostate cancer,
Reichlin et al. [41] identified similar navigation and
content-related issues that could impede user experi-
ences. These studies indicated the importance of forma-
tive usability testing to improve new online programs
prior to field testing. Findings from the current usability
testing concur with this viewpoint.
There are several limitations with this study. First, the
testing was conducted with participants with a long dis-
ease duration (median = 5 years), hence the view of those
with a recent diagnosis was under represented. Second,
since only two out of 15 participants were men, our
findings might not reflect the full range of user experi-
ence of men. Third, most participants were educated
and computer-savvy; hence the results may not be
generalizable to people who are less educated or
computer-savvy. Future studies including these popula-
tions will be important as they may be in greater need of
learning about options, risks and benefits, and exploring
their own preferences and engaging in shared decision-
making. Fourth, we were unable to address all usability
issues identified by participants since some components
were already finalized at the time of the testing (e.g., the
animated videos). Our choice of animation style was
based on a balance between aesthetic and budgetary
constraints. Although some participants responded posi-
tively to the animated graphic novel approach, others
considered it lacking sophistication. Finally, due to the
small sample size, we were unable to further explore the
influence of demographic characteristics (e.g., age, sex,
education level), disease characteristics (e.g., disease dur-
ation and severity) and individuals’ internet use (e.g.,
time spent on internet per day) on the usability scores.
This is important because some of the preferences (e.g.,
animations) may be associated with specific patient char-
acteristics, which if known, would assist in designing
future decision aids targeted to particular populations.
Despite the limitations, findings from the usability
testing have allowed us to refine the ANSWER proto-
type. Recognizing that usability issues are major barriers
to the adoption of health information technology [42],
we have taken steps to address them over the course
of the ANSWER’s development. Yen and Bakkenrecommend three levels of usability evaluation [43]. The
first level aims to identify product components and
functions needed by users to accomplish a task (i.e.,
user-task interaction). Methodology includes direct ob-
servation and needs assessment using qualitative or
survey methodology. The second level assesses the user-
task-program interaction using methods such as heuris-
tic evaluation [44], cognitive walkthrough [45], and the
think aloud technique [46,47]. The third level examines
the complex interaction among users, tasks, the program
and the environment using a variety of experimental and
observational designs. All three levels are addressed in
the ANSWER development and were shown to be help-
ful for different aspects of refining the tool.
Strengths of the study include the emphasis on user
experiences. The ANSWER tool was informed by our
previous qualitative research on RA patients’ help-
seeking experience, especially their challenges in making
medication decisions [29]. In addition, patient/consumer
collaborators were involved at the outset to provide in-
put on the program design. We subsequently evaluated
the user-task-program interaction in the current usabil-
ity testing and addressed all modifiable navigation issues.
The next step will be to evaluate the ANSWER in a
proof-of-concept field study with patients who are con-
sidering methotrexate for treating RA. In addition to
using the tool online, individuals will be able print the
one-page summary of their questions, concerns and pre-
ferred option to bring to their rheumatologist appoint-
ment. As such, they will have the full experience of
shared decision-making. Our goal will be to assess the
extent to which the ANSWER reduces decisional con-
flict and improves self-management knowledge and skills
in patients who are considering methotrexate for RA
[16].
Conclusions
We have developed a user-friendly online decision aid to
assist patients in making informed decision about using
methotrexate for RA. Although the SUS score indicated
high usability before and after major modification, find-
ings from the think-aloud sessions illustrated areas that
required further refinement. Our results highlight the
importance of formative evaluation in usability testing.
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